الفهرس 
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Portal vein thrombosis is a common complication of HCC and leads to the classification of these patients as advanced stage. Activation of coagulation and fibrinolysis is associated with tumor progression, and prognosis. So, we hypothesized that the level of activated factor XII and D-dimer will increase in HCC patients with portal vein thrombosis. Objectives: We aimed to explore the role of activated factor XII and D-dimmer in prediction of portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Patients and Methods: This cross-sectional study was conducted for two years from (9-2019 to 9-2021) on 90 patients with cirrhosis of the liver, and the patients were divided into four groups: cirrhosis, cirrhosis with portal vein thrombosis, hepatocellular carcinoma and hepatocellular carcinoma with portal vein thrombosis. All participants underwent the following : history taking, clinical examination and laboratory tests, which are hepatitis C, hepatitis B virus, HIV, complete blood picture, blood flow index, serum albumin and serum bilirubin (total and direct) , liver enzymes, alpha-fetoprotein, serum creatinine, activated factor XII and D-dimer, with the following radiological investigations: Doppler ultrasound on the portal venous system, Tri-phase abdominal pelvic CT and or magnetic resonance imaging with dynamic contrast for all patients included. Results: This study showed an increase in the value of activated factor XII and dimer significantly in hepatocellular carcinoma with portal vein thrombosis group than in cirrhotic group and hepatocellular carcinoma group. Conclusion : Activated factor XII and dimer can be used for early prediction of portal vein thrombosis in cirrhotic patients and hepatocellular carcinoma patients.